0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Live Biotherapeutic Products (LBP) CDMO Service Market Research Report 2026
Published Date: 2026-01-23
|
Report Code: QYRE-Auto-29S18319
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Live Biotherapeutic Products LBP CDMO Service Market Research Report 2024
BUY CHAPTERS

Global Live Biotherapeutic Products (LBP) CDMO Service Market Research Report 2026

Code: QYRE-Auto-29S18319
Report
2026-01-23
Pages:120
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Live Biotherapeutic Products (LBP) CDMO Service Market Size

The global Live Biotherapeutic Products (LBP) CDMO Service market was valued at US$ 158 million in 2025 and is anticipated to reach US$ 605 million by 2032, at a CAGR of 21.5% from 2026 to 2032.

Live Biotherapeutic Products (LBP) CDMO Service Market

Live Biotherapeutic Products (LBP) CDMO Service Market

Live Biotherapeutic Products (LBPs) are biotherapeutic products based on live microorganisms that are intended to treat or prevent disease by modulating the microbiome. These products are usually prepared from specific strains of microorganisms that have potential therapeutic effects, such as improving gut health, boosting the immune system, or reducing inflammation.CDMOs specializing in these fields have the expertise and infrastructure to support developing and manufacturing these complex therapies, which require specialized equipment and facilities. As a result, pharmaceutical and biotech companies can outsource their production to CDMOs, allowing them to focus on research and development.
The North American market for Live Biotherapeutic Products (LBP) CDMO Service is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Live Biotherapeutic Products (LBP) CDMO Service is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The global market for Live Biotherapeutic Products (LBP) CDMO Service in Digestive System Diseases is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 to 2032.
Major global companies of Live Biotherapeutic Products (LBP) CDMO Service include Lallemand Health Solutions, Wacker Chemie AG, Biose Industrie, List Biological Labs, Inc., NIZO, SGS (Quay Pharmaceuticals), Assembly Biosciences, Inc., Recipharm (Arranta Bio), Bacthera (Novonesis+Lonza), Smaltis, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Live Biotherapeutic Products (LBP) CDMO Service market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Live Biotherapeutic Products (LBP) CDMO Service. The Live Biotherapeutic Products (LBP) CDMO Service market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Live Biotherapeutic Products (LBP) CDMO Service market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Live Biotherapeutic Products (LBP) CDMO Service manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of Live Biotherapeutic Products (LBP) CDMO Service Market Report

Report Metric Details
Report Name Live Biotherapeutic Products (LBP) CDMO Service Market
Accounted market size in 2025 US$ 158 million
Forecasted market size in 2032 US$ 605 million
CAGR 21.5%
Base Year 2025
Forecasted years 2026 - 2032
Segment by Type
  • Solid Dosage Form
  • Liquid Dosage Form
Segment by Application
  • Digestive System Diseases
  • Immune System Diseases
  • Metabolic Diseases
  • Other
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Lallemand Health Solutions, Wacker Chemie AG, Biose Industrie, List Biological Labs, Inc., NIZO, SGS (Quay Pharmaceuticals), Assembly Biosciences, Inc., Recipharm (Arranta Bio), Bacthera (Novonesis+Lonza), Smaltis, Lonza, vermicon AG, Cerbios-Pharma SA
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
  • Chapter 3: Provides a detailed view of the competitive landscape for Live Biotherapeutic Products (LBP) CDMO Service companies, covering revenue share, development plans, and mergers and acquisitions.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
  • Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
  • Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
  • Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
  • Chapter 12: Key findings and conclusions of the report.

FAQ for this report

How fast is Live Biotherapeutic Products (LBP) CDMO Service Market growing?

Ans: The Live Biotherapeutic Products (LBP) CDMO Service Market witnessing a CAGR of 21.5% during the forecast period 2026-2032.

What is the Live Biotherapeutic Products (LBP) CDMO Service Market size in 2032?

Ans: The Live Biotherapeutic Products (LBP) CDMO Service Market size in 2032 will be US$ 605 million.

Who are the main players in the Live Biotherapeutic Products (LBP) CDMO Service Market report?

Ans: The main players in the Live Biotherapeutic Products (LBP) CDMO Service Market are Lallemand Health Solutions, Wacker Chemie AG, Biose Industrie, List Biological Labs, Inc., NIZO, SGS (Quay Pharmaceuticals), Assembly Biosciences, Inc., Recipharm (Arranta Bio), Bacthera (Novonesis+Lonza), Smaltis, Lonza, vermicon AG, Cerbios-Pharma SA

What are the Application segmentation covered in the Live Biotherapeutic Products (LBP) CDMO Service Market report?

Ans: The Applications covered in the Live Biotherapeutic Products (LBP) CDMO Service Market report are Digestive System Diseases, Immune System Diseases, Metabolic Diseases, Other

What are the Type segmentation covered in the Live Biotherapeutic Products (LBP) CDMO Service Market report?

Ans: The Types covered in the Live Biotherapeutic Products (LBP) CDMO Service Market report are Solid Dosage Form, Liquid Dosage Form

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Live Biotherapeutic Products (LBP) CDMO Service Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Solid Dosage Form
1.2.3 Liquid Dosage Form
1.3 Market by Application
1.3.1 Global Live Biotherapeutic Products (LBP) CDMO Service Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Digestive System Diseases
1.3.3 Immune System Diseases
1.3.4 Metabolic Diseases
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Live Biotherapeutic Products (LBP) CDMO Service Market Perspective (2021–2032)
2.2 Global Live Biotherapeutic Products (LBP) CDMO Service Growth Trends by Region
2.2.1 Global Live Biotherapeutic Products (LBP) CDMO Service Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Live Biotherapeutic Products (LBP) CDMO Service Historic Market Size by Region (2021–2026)
2.2.3 Live Biotherapeutic Products (LBP) CDMO Service Forecasted Market Size by Region (2027–2032)
2.3 Live Biotherapeutic Products (LBP) CDMO Service Market Dynamics
2.3.1 Live Biotherapeutic Products (LBP) CDMO Service Industry Trends
2.3.2 Live Biotherapeutic Products (LBP) CDMO Service Market Drivers
2.3.3 Live Biotherapeutic Products (LBP) CDMO Service Market Challenges
2.3.4 Live Biotherapeutic Products (LBP) CDMO Service Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Live Biotherapeutic Products (LBP) CDMO Service Players by Revenue
3.1.1 Global Top Live Biotherapeutic Products (LBP) CDMO Service Players by Revenue (2021–2026)
3.1.2 Global Live Biotherapeutic Products (LBP) CDMO Service Revenue Market Share by Players (2021–2026)
3.2 Global Top Live Biotherapeutic Products (LBP) CDMO Service Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Live Biotherapeutic Products (LBP) CDMO Service Revenue
3.4 Global Live Biotherapeutic Products (LBP) CDMO Service Market Concentration Ratio
3.4.1 Global Live Biotherapeutic Products (LBP) CDMO Service Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Live Biotherapeutic Products (LBP) CDMO Service Revenue in 2025
3.5 Global Key Players of Live Biotherapeutic Products (LBP) CDMO Service Head Offices and Areas Served
3.6 Global Key Players of Live Biotherapeutic Products (LBP) CDMO Service, Products and Applications
3.7 Global Key Players of Live Biotherapeutic Products (LBP) CDMO Service, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Live Biotherapeutic Products (LBP) CDMO Service Breakdown Data by Type
4.1 Global Live Biotherapeutic Products (LBP) CDMO Service Historic Market Size by Type (2021–2026)
4.2 Global Live Biotherapeutic Products (LBP) CDMO Service Forecasted Market Size by Type (2027–2032)
5 Live Biotherapeutic Products (LBP) CDMO Service Breakdown Data by Application
5.1 Global Live Biotherapeutic Products (LBP) CDMO Service Historic Market Size by Application (2021–2026)
5.2 Global Live Biotherapeutic Products (LBP) CDMO Service Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Live Biotherapeutic Products (LBP) CDMO Service Market Size (2021–2032)
6.2 North America Live Biotherapeutic Products (LBP) CDMO Service Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Live Biotherapeutic Products (LBP) CDMO Service Market Size by Country (2021–2026)
6.4 North America Live Biotherapeutic Products (LBP) CDMO Service Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Live Biotherapeutic Products (LBP) CDMO Service Market Size (2021–2032)
7.2 Europe Live Biotherapeutic Products (LBP) CDMO Service Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Live Biotherapeutic Products (LBP) CDMO Service Market Size by Country (2021–2026)
7.4 Europe Live Biotherapeutic Products (LBP) CDMO Service Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Live Biotherapeutic Products (LBP) CDMO Service Market Size (2021–2032)
8.2 Asia-Pacific Live Biotherapeutic Products (LBP) CDMO Service Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Live Biotherapeutic Products (LBP) CDMO Service Market Size by Region (2021–2026)
8.4 Asia-Pacific Live Biotherapeutic Products (LBP) CDMO Service Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Live Biotherapeutic Products (LBP) CDMO Service Market Size (2021–2032)
9.2 Latin America Live Biotherapeutic Products (LBP) CDMO Service Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Live Biotherapeutic Products (LBP) CDMO Service Market Size by Country (2021–2026)
9.4 Latin America Live Biotherapeutic Products (LBP) CDMO Service Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Live Biotherapeutic Products (LBP) CDMO Service Market Size (2021–2032)
10.2 Middle East & Africa Live Biotherapeutic Products (LBP) CDMO Service Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Live Biotherapeutic Products (LBP) CDMO Service Market Size by Country (2021–2026)
10.4 Middle East & Africa Live Biotherapeutic Products (LBP) CDMO Service Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Lallemand Health Solutions
11.1.1 Lallemand Health Solutions Company Details
11.1.2 Lallemand Health Solutions Business Overview
11.1.3 Lallemand Health Solutions Live Biotherapeutic Products (LBP) CDMO Service Introduction
11.1.4 Lallemand Health Solutions Revenue in Live Biotherapeutic Products (LBP) CDMO Service Business (2021–2026)
11.1.5 Lallemand Health Solutions Recent Development
11.2 Wacker Chemie AG
11.2.1 Wacker Chemie AG Company Details
11.2.2 Wacker Chemie AG Business Overview
11.2.3 Wacker Chemie AG Live Biotherapeutic Products (LBP) CDMO Service Introduction
11.2.4 Wacker Chemie AG Revenue in Live Biotherapeutic Products (LBP) CDMO Service Business (2021–2026)
11.2.5 Wacker Chemie AG Recent Development
11.3 Biose Industrie
11.3.1 Biose Industrie Company Details
11.3.2 Biose Industrie Business Overview
11.3.3 Biose Industrie Live Biotherapeutic Products (LBP) CDMO Service Introduction
11.3.4 Biose Industrie Revenue in Live Biotherapeutic Products (LBP) CDMO Service Business (2021–2026)
11.3.5 Biose Industrie Recent Development
11.4 List Biological Labs, Inc.
11.4.1 List Biological Labs, Inc. Company Details
11.4.2 List Biological Labs, Inc. Business Overview
11.4.3 List Biological Labs, Inc. Live Biotherapeutic Products (LBP) CDMO Service Introduction
11.4.4 List Biological Labs, Inc. Revenue in Live Biotherapeutic Products (LBP) CDMO Service Business (2021–2026)
11.4.5 List Biological Labs, Inc. Recent Development
11.5 NIZO
11.5.1 NIZO Company Details
11.5.2 NIZO Business Overview
11.5.3 NIZO Live Biotherapeutic Products (LBP) CDMO Service Introduction
11.5.4 NIZO Revenue in Live Biotherapeutic Products (LBP) CDMO Service Business (2021–2026)
11.5.5 NIZO Recent Development
11.6 SGS (Quay Pharmaceuticals)
11.6.1 SGS (Quay Pharmaceuticals) Company Details
11.6.2 SGS (Quay Pharmaceuticals) Business Overview
11.6.3 SGS (Quay Pharmaceuticals) Live Biotherapeutic Products (LBP) CDMO Service Introduction
11.6.4 SGS (Quay Pharmaceuticals) Revenue in Live Biotherapeutic Products (LBP) CDMO Service Business (2021–2026)
11.6.5 SGS (Quay Pharmaceuticals) Recent Development
11.7 Assembly Biosciences, Inc.
11.7.1 Assembly Biosciences, Inc. Company Details
11.7.2 Assembly Biosciences, Inc. Business Overview
11.7.3 Assembly Biosciences, Inc. Live Biotherapeutic Products (LBP) CDMO Service Introduction
11.7.4 Assembly Biosciences, Inc. Revenue in Live Biotherapeutic Products (LBP) CDMO Service Business (2021–2026)
11.7.5 Assembly Biosciences, Inc. Recent Development
11.8 Recipharm (Arranta Bio)
11.8.1 Recipharm (Arranta Bio) Company Details
11.8.2 Recipharm (Arranta Bio) Business Overview
11.8.3 Recipharm (Arranta Bio) Live Biotherapeutic Products (LBP) CDMO Service Introduction
11.8.4 Recipharm (Arranta Bio) Revenue in Live Biotherapeutic Products (LBP) CDMO Service Business (2021–2026)
11.8.5 Recipharm (Arranta Bio) Recent Development
11.9 Bacthera (Novonesis+Lonza)
11.9.1 Bacthera (Novonesis+Lonza) Company Details
11.9.2 Bacthera (Novonesis+Lonza) Business Overview
11.9.3 Bacthera (Novonesis+Lonza) Live Biotherapeutic Products (LBP) CDMO Service Introduction
11.9.4 Bacthera (Novonesis+Lonza) Revenue in Live Biotherapeutic Products (LBP) CDMO Service Business (2021–2026)
11.9.5 Bacthera (Novonesis+Lonza) Recent Development
11.10 Smaltis
11.10.1 Smaltis Company Details
11.10.2 Smaltis Business Overview
11.10.3 Smaltis Live Biotherapeutic Products (LBP) CDMO Service Introduction
11.10.4 Smaltis Revenue in Live Biotherapeutic Products (LBP) CDMO Service Business (2021–2026)
11.10.5 Smaltis Recent Development
11.11 Lonza
11.11.1 Lonza Company Details
11.11.2 Lonza Business Overview
11.11.3 Lonza Live Biotherapeutic Products (LBP) CDMO Service Introduction
11.11.4 Lonza Revenue in Live Biotherapeutic Products (LBP) CDMO Service Business (2021–2026)
11.11.5 Lonza Recent Development
11.12 vermicon AG
11.12.1 vermicon AG Company Details
11.12.2 vermicon AG Business Overview
11.12.3 vermicon AG Live Biotherapeutic Products (LBP) CDMO Service Introduction
11.12.4 vermicon AG Revenue in Live Biotherapeutic Products (LBP) CDMO Service Business (2021–2026)
11.12.5 vermicon AG Recent Development
11.13 Cerbios-Pharma SA
11.13.1 Cerbios-Pharma SA Company Details
11.13.2 Cerbios-Pharma SA Business Overview
11.13.3 Cerbios-Pharma SA Live Biotherapeutic Products (LBP) CDMO Service Introduction
11.13.4 Cerbios-Pharma SA Revenue in Live Biotherapeutic Products (LBP) CDMO Service Business (2021–2026)
11.13.5 Cerbios-Pharma SA Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
 Table 1. Global Live Biotherapeutic Products (LBP) CDMO Service Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
 Table 2. Key Players of Solid Dosage Form
 Table 3. Key Players of Liquid Dosage Form
 Table 4. Global Live Biotherapeutic Products (LBP) CDMO Service Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
 Table 5. Global Live Biotherapeutic Products (LBP) CDMO Service Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 6. Global Live Biotherapeutic Products (LBP) CDMO Service Market Size by Region (US$ Million), 2021–2026
 Table 7. Global Live Biotherapeutic Products (LBP) CDMO Service Market Share by Region (2021–2026)
 Table 8. Global Live Biotherapeutic Products (LBP) CDMO Service Forecasted Market Size by Region (US$ Million), 2027–2032
 Table 9. Global Live Biotherapeutic Products (LBP) CDMO Service Market Share by Region (2027–2032)
 Table 10. Live Biotherapeutic Products (LBP) CDMO Service Market Trends
 Table 11. Live Biotherapeutic Products (LBP) CDMO Service Market Drivers
 Table 12. Live Biotherapeutic Products (LBP) CDMO Service Market Challenges
 Table 13. Live Biotherapeutic Products (LBP) CDMO Service Market Restraints
 Table 14. Global Live Biotherapeutic Products (LBP) CDMO Service Revenue by Players (US$ Million), 2021–2026
 Table 15. Global Live Biotherapeutic Products (LBP) CDMO Service Market Share by Players (2021–2026)
 Table 16. Global Top Live Biotherapeutic Products (LBP) CDMO Service Players by Tier (Tier 1, Tier 2, and Tier 3), based on Live Biotherapeutic Products (LBP) CDMO Service Revenue, 2025
 Table 17. Ranking of Global Top Live Biotherapeutic Products (LBP) CDMO Service Companies by Revenue (US$ Million) in 2025
 Table 18. Global 5 Largest Players Market Share by Live Biotherapeutic Products (LBP) CDMO Service Revenue (CR5 and HHI), 2021–2026
 Table 19. Global Key Players of Live Biotherapeutic Products (LBP) CDMO Service, Headquarters and Area Served
 Table 20. Global Key Players of Live Biotherapeutic Products (LBP) CDMO Service, Products and Applications
 Table 21. Global Key Players of Live Biotherapeutic Products (LBP) CDMO Service, Date of General Availability (GA)
 Table 22. Mergers and Acquisitions, Expansion Plans
 Table 23. Global Live Biotherapeutic Products (LBP) CDMO Service Market Size by Type (US$ Million), 2021–2026
 Table 24. Global Live Biotherapeutic Products (LBP) CDMO Service Revenue Market Share by Type (2021–2026)
 Table 25. Global Live Biotherapeutic Products (LBP) CDMO Service Forecasted Market Size by Type (US$ Million), 2027–2032
 Table 26. Global Live Biotherapeutic Products (LBP) CDMO Service Revenue Market Share by Type (2027–2032)
 Table 27. Global Live Biotherapeutic Products (LBP) CDMO Service Market Size by Application (US$ Million), 2021–2026
 Table 28. Global Live Biotherapeutic Products (LBP) CDMO Service Revenue Market Share by Application (2021–2026)
 Table 29. Global Live Biotherapeutic Products (LBP) CDMO Service Forecasted Market Size by Application (US$ Million), 2027–2032
 Table 30. Global Live Biotherapeutic Products (LBP) CDMO Service Revenue Market Share by Application (2027–2032)
 Table 31. North America Live Biotherapeutic Products (LBP) CDMO Service Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 32. North America Live Biotherapeutic Products (LBP) CDMO Service Market Size by Country (US$ Million), 2021–2026
 Table 33. North America Live Biotherapeutic Products (LBP) CDMO Service Market Size by Country (US$ Million), 2027–2032
 Table 34. Europe Live Biotherapeutic Products (LBP) CDMO Service Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 35. Europe Live Biotherapeutic Products (LBP) CDMO Service Market Size by Country (US$ Million), 2021–2026
 Table 36. Europe Live Biotherapeutic Products (LBP) CDMO Service Market Size by Country (US$ Million), 2027–2032
 Table 37. Asia-Pacific Live Biotherapeutic Products (LBP) CDMO Service Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 38. Asia-Pacific Live Biotherapeutic Products (LBP) CDMO Service Market Size by Region (US$ Million), 2021–2026
 Table 39. Asia-Pacific Live Biotherapeutic Products (LBP) CDMO Service Market Size by Region (US$ Million), 2027–2032
 Table 40. Latin America Live Biotherapeutic Products (LBP) CDMO Service Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 41. Latin America Live Biotherapeutic Products (LBP) CDMO Service Market Size by Country (US$ Million), 2021–2026
 Table 42. Latin America Live Biotherapeutic Products (LBP) CDMO Service Market Size by Country (US$ Million), 2027–2032
 Table 43. Middle East & Africa Live Biotherapeutic Products (LBP) CDMO Service Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 44. Middle East & Africa Live Biotherapeutic Products (LBP) CDMO Service Market Size by Country (US$ Million), 2021–2026
 Table 45. Middle East & Africa Live Biotherapeutic Products (LBP) CDMO Service Market Size by Country (US$ Million), 2027–2032
 Table 46. Lallemand Health Solutions Company Details
 Table 47. Lallemand Health Solutions Business Overview
 Table 48. Lallemand Health Solutions Live Biotherapeutic Products (LBP) CDMO Service Product
 Table 49. Lallemand Health Solutions Revenue in Live Biotherapeutic Products (LBP) CDMO Service Business (US$ Million), 2021–2026
 Table 50. Lallemand Health Solutions Recent Development
 Table 51. Wacker Chemie AG Company Details
 Table 52. Wacker Chemie AG Business Overview
 Table 53. Wacker Chemie AG Live Biotherapeutic Products (LBP) CDMO Service Product
 Table 54. Wacker Chemie AG Revenue in Live Biotherapeutic Products (LBP) CDMO Service Business (US$ Million), 2021–2026
 Table 55. Wacker Chemie AG Recent Development
 Table 56. Biose Industrie Company Details
 Table 57. Biose Industrie Business Overview
 Table 58. Biose Industrie Live Biotherapeutic Products (LBP) CDMO Service Product
 Table 59. Biose Industrie Revenue in Live Biotherapeutic Products (LBP) CDMO Service Business (US$ Million), 2021–2026
 Table 60. Biose Industrie Recent Development
 Table 61. List Biological Labs, Inc. Company Details
 Table 62. List Biological Labs, Inc. Business Overview
 Table 63. List Biological Labs, Inc. Live Biotherapeutic Products (LBP) CDMO Service Product
 Table 64. List Biological Labs, Inc. Revenue in Live Biotherapeutic Products (LBP) CDMO Service Business (US$ Million), 2021–2026
 Table 65. List Biological Labs, Inc. Recent Development
 Table 66. NIZO Company Details
 Table 67. NIZO Business Overview
 Table 68. NIZO Live Biotherapeutic Products (LBP) CDMO Service Product
 Table 69. NIZO Revenue in Live Biotherapeutic Products (LBP) CDMO Service Business (US$ Million), 2021–2026
 Table 70. NIZO Recent Development
 Table 71. SGS (Quay Pharmaceuticals) Company Details
 Table 72. SGS (Quay Pharmaceuticals) Business Overview
 Table 73. SGS (Quay Pharmaceuticals) Live Biotherapeutic Products (LBP) CDMO Service Product
 Table 74. SGS (Quay Pharmaceuticals) Revenue in Live Biotherapeutic Products (LBP) CDMO Service Business (US$ Million), 2021–2026
 Table 75. SGS (Quay Pharmaceuticals) Recent Development
 Table 76. Assembly Biosciences, Inc. Company Details
 Table 77. Assembly Biosciences, Inc. Business Overview
 Table 78. Assembly Biosciences, Inc. Live Biotherapeutic Products (LBP) CDMO Service Product
 Table 79. Assembly Biosciences, Inc. Revenue in Live Biotherapeutic Products (LBP) CDMO Service Business (US$ Million), 2021–2026
 Table 80. Assembly Biosciences, Inc. Recent Development
 Table 81. Recipharm (Arranta Bio) Company Details
 Table 82. Recipharm (Arranta Bio) Business Overview
 Table 83. Recipharm (Arranta Bio) Live Biotherapeutic Products (LBP) CDMO Service Product
 Table 84. Recipharm (Arranta Bio) Revenue in Live Biotherapeutic Products (LBP) CDMO Service Business (US$ Million), 2021–2026
 Table 85. Recipharm (Arranta Bio) Recent Development
 Table 86. Bacthera (Novonesis+Lonza) Company Details
 Table 87. Bacthera (Novonesis+Lonza) Business Overview
 Table 88. Bacthera (Novonesis+Lonza) Live Biotherapeutic Products (LBP) CDMO Service Product
 Table 89. Bacthera (Novonesis+Lonza) Revenue in Live Biotherapeutic Products (LBP) CDMO Service Business (US$ Million), 2021–2026
 Table 90. Bacthera (Novonesis+Lonza) Recent Development
 Table 91. Smaltis Company Details
 Table 92. Smaltis Business Overview
 Table 93. Smaltis Live Biotherapeutic Products (LBP) CDMO Service Product
 Table 94. Smaltis Revenue in Live Biotherapeutic Products (LBP) CDMO Service Business (US$ Million), 2021–2026
 Table 95. Smaltis Recent Development
 Table 96. Lonza Company Details
 Table 97. Lonza Business Overview
 Table 98. Lonza Live Biotherapeutic Products (LBP) CDMO Service Product
 Table 99. Lonza Revenue in Live Biotherapeutic Products (LBP) CDMO Service Business (US$ Million), 2021–2026
 Table 100. Lonza Recent Development
 Table 101. vermicon AG Company Details
 Table 102. vermicon AG Business Overview
 Table 103. vermicon AG Live Biotherapeutic Products (LBP) CDMO Service Product
 Table 104. vermicon AG Revenue in Live Biotherapeutic Products (LBP) CDMO Service Business (US$ Million), 2021–2026
 Table 105. vermicon AG Recent Development
 Table 106. Cerbios-Pharma SA Company Details
 Table 107. Cerbios-Pharma SA Business Overview
 Table 108. Cerbios-Pharma SA Live Biotherapeutic Products (LBP) CDMO Service Product
 Table 109. Cerbios-Pharma SA Revenue in Live Biotherapeutic Products (LBP) CDMO Service Business (US$ Million), 2021–2026
 Table 110. Cerbios-Pharma SA Recent Development
 Table 111. Research Programs/Design for This Report
 Table 112. Key Data Information from Secondary Sources
 Table 113. Key Data Information from Primary Sources
 Table 114. Authors List of This Report


List of Figures
 Figure 1. Live Biotherapeutic Products (LBP) CDMO Service Picture
 Figure 2. Global Live Biotherapeutic Products (LBP) CDMO Service Market Size Comparison by Type (US$ Million), 2021–2032
 Figure 3. Global Live Biotherapeutic Products (LBP) CDMO Service Market Share by Type: 2025 vs 2032
 Figure 4. Solid Dosage Form Features
 Figure 5. Liquid Dosage Form Features
 Figure 6. Global Live Biotherapeutic Products (LBP) CDMO Service Market Size by Application (US$ Million), 2021–2032
 Figure 7. Global Live Biotherapeutic Products (LBP) CDMO Service Market Share by Application: 2025 vs 2032
 Figure 8. Digestive System Diseases Case Studies
 Figure 9. Immune System Diseases Case Studies
 Figure 10. Metabolic Diseases Case Studies
 Figure 11. Other Case Studies
 Figure 12. Live Biotherapeutic Products (LBP) CDMO Service Report Years Considered
 Figure 13. Global Live Biotherapeutic Products (LBP) CDMO Service Market Size (US$ Million), Year-over-Year: 2021–2032
 Figure 14. Global Live Biotherapeutic Products (LBP) CDMO Service Market Size, (US$ Million), 2021 vs 2025 vs 2032
 Figure 15. Global Live Biotherapeutic Products (LBP) CDMO Service Market Share by Region: 2025 vs 2032
 Figure 16. Global Live Biotherapeutic Products (LBP) CDMO Service Market Share by Players in 2025
 Figure 17. Global Live Biotherapeutic Products (LBP) CDMO Service Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
 Figure 18. The Top 10 and 5 Players Market Share by Live Biotherapeutic Products (LBP) CDMO Service Revenue in 2025
 Figure 19. North America Live Biotherapeutic Products (LBP) CDMO Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 20. North America Live Biotherapeutic Products (LBP) CDMO Service Market Share by Country (2021–2032)
 Figure 21. United States Live Biotherapeutic Products (LBP) CDMO Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 22. Canada Live Biotherapeutic Products (LBP) CDMO Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 23. Europe Live Biotherapeutic Products (LBP) CDMO Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 24. Europe Live Biotherapeutic Products (LBP) CDMO Service Market Share by Country (2021–2032)
 Figure 25. Germany Live Biotherapeutic Products (LBP) CDMO Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 26. France Live Biotherapeutic Products (LBP) CDMO Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 27. U.K. Live Biotherapeutic Products (LBP) CDMO Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 28. Italy Live Biotherapeutic Products (LBP) CDMO Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 29. Russia Live Biotherapeutic Products (LBP) CDMO Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 30. Ireland Live Biotherapeutic Products (LBP) CDMO Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 31. Asia-Pacific Live Biotherapeutic Products (LBP) CDMO Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 32. Asia-Pacific Live Biotherapeutic Products (LBP) CDMO Service Market Share by Region (2021–2032)
 Figure 33. China Live Biotherapeutic Products (LBP) CDMO Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 34. Japan Live Biotherapeutic Products (LBP) CDMO Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 35. South Korea Live Biotherapeutic Products (LBP) CDMO Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 36. Southeast Asia Live Biotherapeutic Products (LBP) CDMO Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 37. India Live Biotherapeutic Products (LBP) CDMO Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 38. Australia & New Zealand Live Biotherapeutic Products (LBP) CDMO Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 39. Latin America Live Biotherapeutic Products (LBP) CDMO Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 40. Latin America Live Biotherapeutic Products (LBP) CDMO Service Market Share by Country (2021–2032)
 Figure 41. Mexico Live Biotherapeutic Products (LBP) CDMO Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 42. Brazil Live Biotherapeutic Products (LBP) CDMO Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 43. Middle East & Africa Live Biotherapeutic Products (LBP) CDMO Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 44. Middle East & Africa Live Biotherapeutic Products (LBP) CDMO Service Market Share by Country (2021–2032)
 Figure 45. Israel Live Biotherapeutic Products (LBP) CDMO Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 46. Saudi Arabia Live Biotherapeutic Products (LBP) CDMO Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 47. UAE Live Biotherapeutic Products (LBP) CDMO Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 48. Lallemand Health Solutions Revenue Growth Rate in Live Biotherapeutic Products (LBP) CDMO Service Business (2021–2026)
 Figure 49. Wacker Chemie AG Revenue Growth Rate in Live Biotherapeutic Products (LBP) CDMO Service Business (2021–2026)
 Figure 50. Biose Industrie Revenue Growth Rate in Live Biotherapeutic Products (LBP) CDMO Service Business (2021–2026)
 Figure 51. List Biological Labs, Inc. Revenue Growth Rate in Live Biotherapeutic Products (LBP) CDMO Service Business (2021–2026)
 Figure 52. NIZO Revenue Growth Rate in Live Biotherapeutic Products (LBP) CDMO Service Business (2021–2026)
 Figure 53. SGS (Quay Pharmaceuticals) Revenue Growth Rate in Live Biotherapeutic Products (LBP) CDMO Service Business (2021–2026)
 Figure 54. Assembly Biosciences, Inc. Revenue Growth Rate in Live Biotherapeutic Products (LBP) CDMO Service Business (2021–2026)
 Figure 55. Recipharm (Arranta Bio) Revenue Growth Rate in Live Biotherapeutic Products (LBP) CDMO Service Business (2021–2026)
 Figure 56. Bacthera (Novonesis+Lonza) Revenue Growth Rate in Live Biotherapeutic Products (LBP) CDMO Service Business (2021–2026)
 Figure 57. Smaltis Revenue Growth Rate in Live Biotherapeutic Products (LBP) CDMO Service Business (2021–2026)
 Figure 58. Lonza Revenue Growth Rate in Live Biotherapeutic Products (LBP) CDMO Service Business (2021–2026)
 Figure 59. vermicon AG Revenue Growth Rate in Live Biotherapeutic Products (LBP) CDMO Service Business (2021–2026)
 Figure 60. Cerbios-Pharma SA Revenue Growth Rate in Live Biotherapeutic Products (LBP) CDMO Service Business (2021–2026)
 Figure 61. Bottom-up and Top-down Approaches for This Report
 Figure 62. Data Triangulation
 Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Novocure